Upon AR pathway inhibition, there may be a consequent up-regulation of PSMA; however, if the tumor undergoes neuroendocrine differentiation (NED), driven by factors like N-Myc and EZH2, epigenetic silencing of FOLH1 results in PSMA-low or -negative subclones [75]. The gene discussed is MYCN; the disease is neoplasm.